Haemonetics to announce Q1 FY27 results on August 6, 2026

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights

Haemonetics Corporation will release its Q1 FY27 financial results on August 6, 2026, followed by an investor conference call. A live webcast and a one-year replay will be available for access.

powered bylight_fuzz_icon
45096144

*this image is generated using AI for illustrative purposes only.

Haemonetics Corporation announced it will publish its first quarter fiscal year 2027 financial results on August 6, 2026. The company will hold a conference call with investors and analysts to discuss the results and address questions at 8:00 am ET on the same day. The financial results will be released at 6:00 am ET.

Conference Call Details

Investors can access the conference call via teleconference after completing registration. Participants will receive a dial-in number and a personalized PIN. Joining 10 minutes prior to the event start is recommended.

A live webcast of the call will be available on Haemonetics' investor relations website. The webcast link is provided for access.

Replay Availability

A replay of the conference call and webcast will be accessible for one year starting at 11:00 am ET on August 6, 2026. The replay can be accessed using the conference call webcast link provided in the release.

Key Dates and Times

Event Date Time (ET)
Financial Results Release August 6, 2026 6:00 am
Conference Call August 6, 2026 8:00 am
Replay Availability August 6, 2026 11:00 am
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What strategic initiatives does Haemonetics plan to prioritize in FY 2027?

How might market conditions impact Haemonetics' financial performance in the upcoming quarter?

What key metrics or trends should investors watch for during the conference call?

like19
dislike

BTIG reiterates Buy rating on Haemonetics with $84 target

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics, maintaining a price target of $84.

powered bylight_fuzz_icon
44020909

*this image is generated using AI for illustrative purposes only.

BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics, maintaining a price target of $84. The rating affirmation signals continued confidence in the company's stock performance potential.

Analyst Rating and Price Target

The research note from BTIG reinforces the positive outlook on Haemonetics. The $84 price target provides a specific benchmark for investors regarding the stock's valuation expectations.

Firm Analyst Rating Price Target
BTIG Marie Thibault Buy $84
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts does BTIG expect to drive Haemonetics' stock toward the $84 price target?

How might recent market trends in the medical technology sector impact Haemonetics' growth trajectory?

What are the potential risks or challenges that could hinder Haemonetics from achieving this bullish outlook?

like20
dislike

More News on Haemonetics Corp